Equillium (EQ) Price & Analysis

Compare

707 Followers

EQ Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.27 - $1.50

Previous CloseN/A

Volume484.47K

Average Volume (3M)462.88K

Market Cap

$14.25M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.32

Next Earnings

Aug 06, 2025

EPS Estimate

-0.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding35,719,320

10 Day Avg. Volume312,386

30 Day Avg. Volume462,879

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$0.50

Price Target Upside31.58% Upside

Rating ConsensusHold

Number of Analyst Covering0

Bulls Say, Bears Say

Bulls Say

EarningsEQ reported positive topline results from a Phase 2 study of lead asset itolizumab in ulcerative colitis, demonstrating encouraging activity and being well tolerated with no notable safety signals.

ValuationThe modest valuation for EQ at current levels, combined with positive data, successful regulatory interaction, and additional capital, could drive meaningful upside to EQ shares.

Bears Say

Clinical Trial ResultsThe EQUATOR trial failed to achieve its primary endpoint of complete response at Day 29 and both key secondary endpoints.

Financial UncertaintyThe company's cash and equivalents were $14.5 million, providing runway into the third quarter of 2025, which creates a significant financing overhang for EQ shares.

Regulatory ChallengesThe FDA declined to support an accelerated approval pathway for itolizumab in first-line treatment of acute graft-versus-host disease.

Equillium News

Equillium Granted Extension for Nasdaq Compliance

Equillium ( ($EQ) ) has shared an announcement. Equillium, Inc. received a notice from Nasdaq on December 13,...

2M ago

Equillium Holds Annual Stockholders Meeting on Key Proposals

Equillium ( ($EQ) ) just unveiled an update. On May 21, 2025, Equillium, Inc. held its Annual Meeting...

2M ago

Leerink says Equillium’s itolizumab news ‘disappointing but not surprising’

Leerink notes that Equillium (EQ) announced that the FDA declined to support an accelerated approval pathway for itolizumab...

3M ago

Equillium says FDA declines Breakthrough Therapy designation for itolizumab

Equillium (EQ) announced that the company has received feedback from its Type D meeting with the FDA to...

3M ago

Equillium’s Hold Rating: Clinical and Financial Challenges Amid Uncertain Regulatory Pathway

Leerink Partners analyst Thomas Smith downgraded the rating on Equillium (EQ – Research Report) to a Hold today,...

4M ago

Equillium downgraded to Market Perform from Outperform at Leerink

Leerink analyst Thomas Smith downgraded Equillium (EQ) to Market Perform from Outperform with a price target of $1,...

4M ago

Equillium Reports 2024 Financials and Clinical Milestones

Equillium ( ($EQ) ) has released its Q4 earnings. Here is a breakdown of the information Equillium presented...

4M ago

Morning Movers: Nvidia slips following report of H20 chip shortage in China

Stock index futures are exhibiting mixed movements as investors digest the implications of President Donald Trump’s announcement of...

4M ago

GME

Equillium reports EQUATOR study did not improve complete, overall response rates

Equillium (EQ) announced topline data from the Phase 3 EQUATOR study evaluating itolizumab in first-line treatment of patients...

4M ago

Equillium reports Q4 EPS (16c) vs. (7c) last year

Reports Q4 revenue $4.39M vs. $9.21M last year. “This morning, following considerable efforts by our clinical team, we...

4M ago

EQ Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Equillium (EQ) is scheduled to report 4th quarter earnings on 03/26/2025. Regarding Q4 estimates, Wall Street analysts expect...

4M ago

Equillium announces itolizumab study achieves secondary endpoint

Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of...

6M ago

Equillium Announces Board and Audit Committee Changes

Equillium ( ($EQ) ) has shared an update. Equillium, Inc. announced changes in its Board of Directors with...

8M ago

Equillium’s Q3 Financials and Clinical Progress in Focus

Equillium ( ($EQ) ) has released its Q3 earnings. Here is a breakdown of the information Equillium presented...

9M ago

EQ FAQ

What was Equillium’s price range in the past 12 months?

Equillium lowest stock price was $0.27 and its highest was $1.50 in the past 12 months.

What is Equillium’s market cap?

Equillium’s market cap is $14.25M.

When is Equillium’s upcoming earnings report date?

Equillium’s upcoming earnings report date is Aug 06, 2025 which is in 5 days.

How were Equillium’s earnings last quarter?

Equillium released its earnings results on May 08, 2025. The company reported -$0.335 earnings per share for the quarter, the consensus estimate of -$0.335 by $0.

Is Equillium overvalued?

According to Wall Street analysts Equillium’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Equillium pay dividends?

Equillium does not currently pay dividends.

What is Equillium’s EPS estimate?

Equillium’s EPS estimate is -0.23.

How many shares outstanding does Equillium have?

Equillium has 35,719,320 shares outstanding.

What happened to Equillium’s price movement after its last earnings report?

Equillium reported an EPS of -$0.335 in its last earnings report, expectations of -$0.335. Following the earnings report the stock price went up 2.564%.

Which hedge fund is a major shareholder of Equillium?

Currently, no hedge funds are holding shares in EQ

Equillium Stock Smart Score

Neutral

Fundamentals

Return on Equity

-88.32%

Trailing 12-Months

Asset Growth

-61.63%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Equillium

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.